Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease
Xavier Pouwels(University of Twente), Hendrik Koffijberg(University Medical Center Utrecht), Cornelis Boersma(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Marc Thelen(Radboud University Nijmegen), Marc H. Hemmelder(Nefrovisie), Ronald W. van Etten(Amphia Ziekenhuis), Dominique van Mil(University Medical Center Groningen), Marloes Langelaan(Amphia Ziekenhuis), Ron T. Gansevoort, Birgitte Evers-Roeten, Lyanne M. Kieneker(University Medical Center Groningen)
Cited by 34
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990